Comparative Pharmacology
Head-to-head clinical analysis: GILENYA versus PIASKY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILENYA versus PIASKY.
GILENYA vs PIASKY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator. It is phosphorylated to fingolimod-phosphate, which binds to S1P receptors 1, 3, 4, and 5. It blocks lymphocyte egress from lymph nodes by acting as a functional antagonist at S1P1 receptors, reducing peripheral blood lymphocyte count and central nervous system inflammation.
PIASKY is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), which irreversibly binds to the active site of BTK, blocking B-cell receptor signaling and inhibiting B-cell proliferation and survival.
0.5 mg orally once daily, with or without food
10 mg orally twice daily
None Documented
None Documented
The terminal elimination half-life of fingolimod is approximately 6–9 days (mean 8.4 days). Due to the prolonged half-life, steady-state is achieved after 1–2 months of daily dosing, and lymphopenia may persist for up to 2 months after treatment cessation.
Terminal elimination half-life is approximately 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 24 hours in severe impairment (CrCl <30 mL/min).
Fingolimod is primarily eliminated via fecal excretion (81%) and to a lesser extent via renal excretion (<1% as unchanged drug). Biliary excretion accounts for a minor portion. The major metabolic pathway is via CYP4F2-mediated hydroxylation, followed by glucuronidation and elimination in feces.
Primarily renal excretion as unchanged drug (approx. 80-90%) with minor biliary/fecal elimination (5-10%).
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator